Compare APPS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPS | COLL |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2012 | 2015 |
| Metric | APPS | COLL |
|---|---|---|
| Price | $10.50 | $22.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $17.00 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 2.5M | 674.2K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $103,569,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $17.68 | $6.73 |
| Revenue Next Year | $11.78 | $1.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 38.55 | 23.62 |
| 52 Week Low | $2.74 | $21.43 |
| 52 Week High | $15.34 | $50.79 |
| Indicator | APPS | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 48.24 |
| Support Level | $10.07 | $21.51 |
| Resistance Level | $10.80 | $23.69 |
| Average True Range (ATR) | 0.68 | 0.65 |
| MACD | -0.07 | 0.31 |
| Stochastic Oscillator | 54.71 | 54.60 |
Digital Turbine Inc is an independent mobile growth platform that levels up the landscape for advertisers, publishers, carriers, and device original equipment manufacturers. The Company offers end-to-end products and solutions leveraging proprietary technology to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. In addition, its products and solutions provide monetization opportunities for OEMs, carriers, and application (app or apps) publishers and developers.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.